Cyanobacterial metabolites as promising drug leads against the M^pro and PL^pro of SARS-CoV-2: an in silico analysis.

ABSTRACT: A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged as the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. Treatment efforts have been severely impeded due to the lack of specific effective antiviral drugs for the treatment of COVID-associated pathologies. In the present research endeavour the inhibitory prospects of cyanobacterial metabolites were assessed at the active binding pockets of the two vital SARS-CoV-2 proteases namely, main protease (M^pro) and the papain-like protease (PL^pro) that proteolytically process viral polyproteins and facilitate viral replication, employing an in silico molecular interaction-based approach. It was evident from our analysis based on the binding energy scores that the metab

SUBMITTER: Naidoo D 

PROVIDER: S-EPMC7441779 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature